Economy

Teva Shares Jump 9% as Innovative Drug Sales Top $1 Billion

Published

Courtroom-sketch editorial illustration of colorful medicine boxes arranged diagonally in a close-up composition

Teva shares rose 9% after the Israeli drugmaker reported $4.142 billion in second-quarter revenue and raised its 2026 sales outlook for Austedo, Ajovy and Uzedy. The three innovative medicines generated more than $1 billion together, up 43% year over year in local-currency terms. Austedo reached $696 million, Ajovy $244 million and Uzedy $77 million, while generic-product revenue fell. Teva posted a $576 million net loss, mainly reflecting expenses tied to the Emalex acquisition, and kept its full-year revenue forecast at $16.5 billion to $16.85 billion.

Sources

Primary sources:1Secondary sources:23

Related stories

  1. Enlight Raises 2026 Guidance as Quarterly Revenue and Income Climb 55%
  2. Supreme Court Dismisses Appeal Over NewMed-Avner Partnership Merger
  3. Check Point Revenue Rises 1% to $674 Million as Subscription Sales Grow 12%
  4. U.S. Awards $58.6 Billion Contract to Rebuild Patriot Stocks
  5. Court Orders Amy Winehouse’s Father to Pay Friends Nearly £1 Million

Something went wrong

We couldn't complete that action. Check your connection and try again.